Full Press Release Details
Recognizes World Kidney Day and National Kidney Month with New
Activities Focused on Raising Awareness for Kidney Disease
VICTORIA, British Columbia--(BUSINESS WIRE)--March 14, 2019--In
recognition of World Kidney Day and National Kidney Month, Aurinia
Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage
biopharmaceutical company with research ongoing in two kidney diseases,
Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS),
today announced a host of activities, including an initiative
with The National Kidney Foundation (NKF), designed to raise
awareness for kidney disease. To find out more and to get involved in
National Kidney Month, Aurinia invites all to:
Explore important resources and activities from NKF and ALL IN,
Aurinia's educational program and support community for people living
with LN, on the ALL IN Program website. Aurinia is working with the
NKF to go #ALLINorange throughout the month of March. ALL IN community
members will receive #ALLINorange buttons to wear to show support for
kidney disease, as well as receive access to helpful information.
Learn more at www.allinforln.com/allinorange
Visit our National Kidney Month calendar on Aurinia's corporate
website to get information about kidney disease and a quick overview
of the important kidney awareness activities happening in March.
Access the calendar here: www.auriniapharma.com/calendar
Re-share, like or comment on the useful resources and surprising facts
about kidney disease that we are posting from our handle @AuriniaPharma
on Twitter and Facebook
"National Kidney Month is so important because it is imperative that
kidney health becomes a part of everyday conversations," said Joseph
Vassalotti, MD, Chief Medical Officer with the National Kidney
Foundation. "Kidney diseases such as lupus nephritis and FSGS can be
devastating for people living with those diseases as well as their
friends, family and loved ones. For these reasons, we are excited to
work with Aurinia to both spread awareness and provide helpful
"Both LN and FSGS are serious and often debilitating diseases for which
there are currently no FDA or EMA approved therapies," said Neil
Solomons, M.D. Chief Medical Officer at Aurinia. "Additionally, LN and
FSGS can lead to end-stage renal disease requiring dialysis or kidney
transplant. In extreme cases these diseases can even lead to death.
Aurinia is committed to raising awareness around these kidney diseases
and to developing innovative products to potentially help," he added.
To learn more about LN, visit ALL IN at www.allinforlupusnephritis.com.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical
company focused on developing and commercializing therapies to treat
targeted patient populations that are impacted by serious diseases with
a high unmet medical need. The company is currently developing an
investigational drug, for the treatment of Lupus Nephritis, Focal
Segmental Glomerulosclerosis and Dry Eye Syndrome. The company is
headquartered in Victoria, British Columbia and focuses its development
efforts globally. For further information, see our website at www.auriniapharma.com.
About Kidney Disease
In the United States 30 million adults are estimated to have chronic
kidney disease-and most aren't aware of it. 1 in 3 American adults are
at risk for chronic kidney disease. Risk factors for kidney
disease include diabetes, high blood pressure, heart disease, obesity
and family history. People of African American, Hispanic, Native
American, Asian or Pacific Islander descent are at increased risk for
developing the disease. African Americans are 3 times more likely than
whites, and Hispanics are nearly 1.5 times more likely than
non-Hispanics to develop end stage renal disease (kidney failure).1
About National Kidney Foundation
The National Kidney Foundation (NKF) is the largest, most comprehensive,
and longstanding patient-centric organization dedicated to the
awareness, prevention, and treatment of kidney disease in the U.S. For
more information about NKF, visit www.kidney.org.
Forward-Looking Statements
Certain of the statements made in this presentation may constitute
forward-looking information within the meaning of applicable Canadian
securities law and forward-looking statements within the meaning of
applicable U.S. securities law. These forward-looking statements or
information include, but are not limited to statements or information
with respect to the projected worth of the lupus nephritis (LN) market,
that voclosporin is potentially a best-in-class calcineurin-inhibitor
(CNI) with robust intellectual property protection and exclusivity and
the likelihood of data exclusivity in major markets, the expectation
that voclosporin will be the only CNI with a label for LN, the expected
progress of the AURORA study; the anticipated commercial potential of
voclosporin for the treatment of LN and FSGS.
When used in these marketing materials, the words "anticipate", "will",
"believe", "estimate", "expect", "intend", "target", "plan", "goals",
"objectives", "may" and other similar words and expressions, identify
forward-looking statements or information.
We have made numerous assumptions about the forward-looking statements
and information contained herein, including among other things,
assumptions about: the market value for the LN program; that another
company will not create a substantial competitive product for Aurinia's
LN business without violating Aurinia's intellectual property rights;
and the size of the LN market. Even though the management of Aurinia
believes that the assumptions made and the expectations represented by
such statements or information are reasonable, there can be no assurance
that the forward-looking information will prove to be accurate.
Forward-looking information by their nature are based on assumptions and
involve known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of Aurinia to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking information.
Should one or more of these risks and uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those described in forward-looking statements or
information. Such risks, uncertainties and other factors include, among
others, the following: the market for the LN business may not be as